Acute myeloid leukemia
Conditions
Interventions
Bone marrow remission group :No interventions
Bone marrow unrelieved group:No interventions
Sponsors
The First Affiliated Hospital of Anhui Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Acute myeloid leukemia was confirmed; 2.It was first treated with Venetoclax combined with hypomethylatied drugs,with or without FLT-3 inhibitor.3.The ineligibility for standard chemo-therapy was determined if the patient matches at least one of the following: (1) 75 years of age or older; (2) one or more of pre-existing conditions including heart failure, chronic stable angina, lung function insufficiency, invasive pulmonary fungal infection and serious infection; (3) an Eastern Cooperative Oncology Group (ECOG) performance-status score of 2 or 4.
Exclusion criteria
Exclusion criteria: 1. The Venetoclax was used for less than seven days; 2.Concurrent use of cytotoxic drugs,lenalidomide and Chidamide should be excluded.;3.Patient who had previously used Venetoclax were excluded,4.Patient who have undergone hematopoietic stem cell transplantation should be excluded.5.Patients with disease in remission should be excluded. 6.Patient without sufficient clinical data .
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Bone marrow remission degree;minimal residual disease; | — |
Secondary
| Measure | Time frame |
|---|---|
| Major hematological adverse events; | — |
Countries
China
Contacts
Public ContactQingshu Zeng
Department of Hematology, The First Affiliated Hospital of Anhui Medical University
Outcome results
None listed